Comerica Bank
KYTX icon

Comerica Bank’s Kyverna Therapeutics KYTX Stock Holding History

Comerica Bank’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-122
Closed -$597 – 3758
2024
Q3 		$597 Sell
122
-30
-20% -$231 ﹤0.01% 3606
2024
Q2 		$1.14K Buy
152
+89
+141% +$1.36K ﹤0.01% 3570
2024
Q1 		$1.56K Buy
+63
New +$1.76K ﹤0.01% 3573

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Comerica Bank's KYTX Position: Q4 2024 in Review

Comerica Bank sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 122 shares — an estimated $597 sold.

Comerica Bank first reported a position in KYTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.56K in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Comerica Bank reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Comerica Bank sold 122 Kyverna Therapeutics shares in Q4 2024, an estimated $597.
  • Comerica Bank first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 3 quarters.
  • Comerica Bank's Kyverna Therapeutics position peaked at $1.56K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Comerica Bank's 13F filing for Q4 2024, filed 14 Feb 2025.